{"entity":{"id":"nct06785636","kind":"trial","name":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC","aka":[],"tldr":"A phase 1/2 trial of Darolutamide in prostate cancer, run by Pathos AI, Inc., now recruiting.","summary":"A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC is a phase 1/2 interventional study registered as NCT06785636 by Pathos AI, Inc., with 120 participants planned, started 2025-02-07 and due to reach its primary completion in 2028-06-30. Interventions recorded: Pocenbrodib, Pocenbrodib and Darolutamide. Conditions listed: mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06785636","url":"https://clinicaltrials.gov/study/NCT06785636"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["darolutamide"],"companies":["pathos-ai"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06785636","phase":"1/2","setting":"PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","sponsor":"Pathos AI, Inc.","enrolled":120,"outcomes":[]},"route":"/trials/nct06785636/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"darolutamide","kind":"drug","name":"Darolutamide","route":"/drugs/darolutamide/"}],"company":[{"id":"pathos-ai","kind":"company","name":"Pathos AI","route":"/companies/pathos-ai/"}]}}